Fulgent Genetics, Inc. (FLGT) News
Filter FLGT News Items
FLGT News Results
|Loading, please wait...|
FLGT News Highlights
- For FLGT, its 30 day story count is now at 30.
- Over the past 29 days, the trend for FLGT's stories per day has been choppy and unclear. It has oscillated between 1 and 12.
- RARE, NGS and BBW are the most mentioned tickers in articles about FLGT.
Latest FLGT News From Around the Web
Below are the latest news stories about Fulgent Genetics Inc that investors may wish to consider to help them evaluate FLGT as an investment opportunity.
Epic Sciences is collaborating with Fulgent Genetics (FLGT -5.9%) to deliver DefineMBC profiling results for patients with metastatic breast cancer (MBC). The partnership links Fulgent's CAP/CLIA certified next generation sequencing services with Epic's cell analysis platform as part of Epic's novel DefineMBC liquid biopsy test. The companies said the DefineMBC includes...
EPIC SCIENCES AND FULGENT GENETICS COLLABORATE TO DELIVER DefineMBC™ RESULTS FOR METASTATIC BREAST CANCER PATIENTS
Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic breast cancer (MBC) patients. The partnership links Fulgent's leading CAP/CLIA certified Next Generation Sequencing services with Epic's best-in-class cell analysis platform as part of Epic's novel DefineMBC liquid biopsy test.
Fulgent Genetics press release (NASDAQ:FLGT): Q4 Non-GAAP EPS of $3.48 beats by $0.81. Revenue of $251.7M beats by $60.6M. Shares -5%. Outlook Q1 2022:T otal Revenue of approximately $245 million; Core Revenue including COVID-19 NGS of approximately $32 million, representing growth of 92% year-over-year; Core Revenue excluding COVID-19 NGS of approximately $22 million...
Fulgent Genetics, Inc. (FLGT) Q4 2021 Earnings Conference Call February 23, 2022 04:30 PM ET Company Participants Nicole Borsje - Investor Relations Ming Hsieh - Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Larry Weiss - Chief Medical Officer Conference Call Participants Kevin...
TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics,” “Fulgent,” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Results: Revenue of $251.7 million Billable tests delivered approximately 2.5 million Core Revenue grew 234%
Shares of Fulgent Genetics (FLGT) are down 12% in after-hours trading despite quarterly results that beat on the top and bottom lines.
No summary available.
Fulgent Genetics (FLGT) announced a strategic investment in Spatial Genomics.FLGT is investing up to $40M to lead Spatial''s series A financing, which totals ~$56M
FLGT earnings call for the period ending December 31, 2021.
TEMPLE CITY, Calif. & PASADENA, Calif., February 23, 2022--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. ("Spatial"), a leading developer of sequential fluorescence in situ hybridization (seqFISH) technology. Fulgent Genetics is investing up to $40 million to lead